Brief: Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity
06/03/2025 14:10
March 6 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN BIOTECH INC: ANNOUNCES ADDITIONAL ANNAMYCIN PATENT ALLOWANCES TO ENHANCE GLOBAL EXCLUSIVITY MOLECULIN BIOTECH INC: NEW PATENTS WILL EXTEND COVERAGE TO MAJOR MARKETS OUTSIDE U.S. Source text: ID:nPn9JBSmfa Further company coverage: MBRX.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM